Selinexor (Xpovio) tablet in combination with dexamethasone has received FDA approval as treatment option for the adult patients with multiple myeloma with no available therapy.

Indication: Treatment of adult patients with relapsed refractory multiple myeloma who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody

Side effects: Leukopenia, neutropenia, thrombocytopenia, anemia, vomiting, nausea, fatigue, diarrhea, fever, decreased appetite and weight, constipation, upper respiratory tract infections and hyponatremia.

Precautions

• Monitor patients for low blood counts, platelets and sodium levels.
• Avoid taking this drug along with other medications that may cause dizziness or confusion and avoid situations where dizziness may be a problem.
• Health care professionals should optimize the patient’s hydration status, blood counts and other medications to avoid dizziness or confusion.

(Source: FDA)

Dr KK Aggarwal

Padma Shri Awardee

President Elect Confederation of Medical Associations in Asia and Oceania   (CMAAO)

Group Editor-in-Chief IJCP Publications

President Heart Care Foundation of India

Past National President IMA